Sclerosing epithelioid fibrosarcoma
Information
- Disease name
- Sclerosing epithelioid fibrosarcoma
- Disease ID
- Description
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| CDK4 | 12 | 57,747,727 | 57,752,310 | 2 |
| PACRG-AS2 | 6 | 163,042,980 | 163,054,161 | 2 |
| PTPRU | 1 | 29,236,516 | 29,325,661 | 2 |
| MIR4728 | 17 | 39,726,495 | 39,726,561 | 2 |
| PACRG-AS3 | 6 | 163,181,714 | 163,192,027 | 2 |
| ALOX12B | 17 | 8,072,636 | 8,087,716 | 2 |
| ARID1A | 1 | 26,696,015 | 26,782,104 | 2 |
| PACRG | 6 | 162,727,132 | 163,315,491 | 2 |
| TSPAN31 | 12 | 57,745,039 | 57,750,219 | 2 |
| MET | 7 | 116,672,196 | 116,798,377 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02180867 | Active, not recruiting | Phase 2/Phase 3 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | July 11, 2014 | December 22, 2024 |
| NCT03600649 | Active, not recruiting | Phase 1 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | June 4, 2018 | December 2025 |
| NCT05266196 | Enrolling by invitation | Phase 1/Phase 2 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | January 15, 2022 | December 2025 |
| NCT03967834 | Recruiting | N/A | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group | April 26, 2021 | April 2031 |